Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEP vs High-Dose Chemotherapy in Poor-Risk Germ Cell Tumors
NCT00002596Phase 3Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 1994
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of carboplatin, cyclophosphamide and etoposide in germ cell tumor (GCT) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Survival and Progression-Free Survival. Started Sep 1994; status: completed.
02
Drugs
carboplatincyclophosphamideetoposide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00002596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002596.